South Africa Rheumatoid Arthritis Therapeutics Market Size & Outlook
South Africa rheumatoid arthritis therapeutics market, 2018-2030 (US$M)
Related Markets
South Africa rheumatoid arthritis therapeutics market highlights
- The South Africa rheumatoid arthritis therapeutics market generated a revenue of USD 125.3 million in 2023 and is expected to reach USD 175.2 million by 2030.
- The South Africa market is expected to grow at a CAGR of 4.9% from 2024 to 2030.
- In terms of segment, biopharmaceuticals was the largest revenue generating molecule in 2023.
- Biopharmaceuticals is the most lucrative molecule segment registering the fastest growth during the forecast period.
Rheumatoid arthritis therapeutics market data book summary
| Market revenue in 2023 | USD 125.3 million |
| Market revenue in 2030 | USD 175.2 million |
| Growth rate | 4.9% (CAGR from 2023 to 2030) |
| Largest segment | Biopharmaceuticals |
| Fastest growing segment | Biopharmaceuticals |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Pharmaceuticals, Biopharmaceuticals |
| Key market players worldwide | Boehringer Ingelheim, Novartis AG ADR, Regeneron Pharmaceuticals Inc, Pfizer Inc, Bristol-Myers Squibb Co, Roche Holding AG, UCB SA, Johnson & Johnson, Amgen Inc, AbbVie Inc |
Other key industry trends
- In terms of revenue, South Africa accounted for 0.5% of the global rheumatoid arthritis therapeutics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, Saudi Arabia rheumatoid arthritis therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- UAE is the fastest growing regional market in Middle East & Africa and is projected to reach USD 65.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Rheumatoid Arthritis Therapeutics Market Scope
Rheumatoid Arthritis Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
South Africa rheumatoid arthritis therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rheumatoid arthritis therapeutics market will help companies and investors design strategic landscapes.
Biopharmaceuticals was the largest segment with a revenue share of 88.67% in 2023. Horizon Databook has segmented the South Africa rheumatoid arthritis therapeutics market based on pharmaceuticals, biopharmaceuticals covering the revenue growth of each sub-segment from 2018 to 2030.
The South Africa rheumatoid arthritis therapeutics market is witnessing significant developments with the introduction of new biosimilar treatments and strategic collaborations. In February 2024, a notable milestone was achieved with the U.S. approval of SIMLANDI (adalimumab-ryvk) injection, developed by Alvotech in partnership with Teva.
This approval marks the first interchangeable high-concentration, citrate-free biosimilar to Humira, a widely used drug in RA treatment. Alvotech, a biotech company, has strategically partnered with global pharmaceutical companies like Teva and local partners such as Cipla/Cipla Gulf/Cipla Med Pro to expand its market reach and leverage local expertise.
This network of partnerships aims to ensure broader accessibility to innovative RA therapies, including SIMLANDI, in key markets like South Africa and across Africa. The introduction of biosimilar alternatives like SIMLANDI could potentially enhance treatment accessibility and affordability for RA patients in South Africa.
Reasons to subscribe to South Africa rheumatoid arthritis therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of South Africa rheumatoid arthritis therapeutics market databook
-
Our clientele includes a mix of rheumatoid arthritis therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the South Africa rheumatoid arthritis therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into South Africa rheumatoid arthritis therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
South Africa rheumatoid arthritis therapeutics market size, by molecule, 2018-2030 (US$M)
South Africa Rheumatoid Arthritis Therapeutics Market Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
